Australia’s health expenditure totalled Euros 58.6 billion, representing 9.1% of gross domestic product (GDP) in the financial year of 2007–2008, which is the same percentage of GDP as the previous year. Australia’s health expenditure as a proportion of GDP has been comparable to that seen in Europe, with most of its spending coming from the government.
Australian healthcare reform
Home/Policies & Legislation
|
Posted 17/12/2010
0
Post your comment
With the election of the government in 2007, a National Health and Hospitals Reform Commission was established to develop a long-term health reform plan and broaden the healthcare agreements between central government and the US. Under the proposed legislation, central government will retain more tax revenues from the states and territories, becoming the majority funder of all public hospitals and taking full control of doctors and frontline health services in Australia. For the first time the government would directly pay hospitals to deliver treatment to patients.
The bill, designed to save taxpayers Euros 1.3 billion over the next five years is passing through the legislative process. Generics’ producers are unhappy with the medicines pricing component of the plans as they argue that they will face the brunt of the cuts.
At the moment the bill’s progress is stalled, and with a wafer-thin government majority, it is not clear when it will reach the statute books.
Related article
Price cuts, legislation and reforms
Reference
Pharmaceuticals in Australia. Datamonitor Healthcare. April 2010.
Source: Reuters
Guidelines
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Canada eliminates phase III trial requirement for biosimilar approvals
Reports
Central America moves toward joint evaluation of biosimilar medicines
The US$52 billion question: can the US keep biosimilars competitive?
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Congress pushes biosimilar bills as interchangeability concerns linger
ANVISA updates understanding on biosimilar interchangeability
China's 12th VBP round accelerates shift to generics and biosimilars dual-track
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Home/Policies & Legislation Posted 15/09/2026
Congress pushes biosimilar bills as interchangeability concerns linger
Home/Policies & Legislation Posted 02/09/2026
ANVISA updates understanding on biosimilar interchangeability
Home/Policies & Legislation Posted 22/07/2026
China's 12th VBP round accelerates shift to generics and biosimilars dual-track
Home/Policies & Legislation Posted 03/07/2026
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment